Advertisement
ANRO vs XTLB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a StrongBuy and XTLB is a StrongBuy.
ANRO sees its Stochastic Oscillator ascends from oversold territory
On October 20, 2026, the Stochastic Oscillator for ANRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 25 instances where the indicator left the oversold zone. In 23 of the 25 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANRO's RSI Indicator exited the oversold zone, 11 of 13 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for ANRO just turned positive on October 20, 2026. Looking at past instances where ANRO's MACD turned positive, the stock continued to rise in 16 of 17 cases over the following month. The odds of a continued upward trend are 90%.
Following a +11.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANRO advanced for three days, in 150 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANRO as a result. In 38 of 47 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
ANRO moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ANRO crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ANRO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.174) is normal, around the industry mean (2.973). P/E Ratio (-10.052) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ANRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
XTLB sees its Stochastic Oscillator climbs out of oversold territory
On October 22, 2026, the Stochastic Oscillator for XTLB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 71 instances where the indicator left the oversold zone. In 55 of the 71 cases the stock moved higher in the following days. This puts the odds of a move higher at over 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XTLB just turned positive on October 22, 2026. Looking at past instances where XTLB's MACD turned positive, the stock continued to rise in 32 of 51 cases over the following month. The odds of a continued upward trend are 63%.
Following a +5.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where XTLB advanced for three days, in 122 of 160 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XTLB as a result. In 121 of 124 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTLB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XTLB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XTLB's P/B Ratio (-103.004) is very low in comparison to the industry average of (2.973). P/E Ratio (-0.616) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.083) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. XTLB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTLB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
XTLB | ||
|---|---|---|
OUTLOOK RATING 1..100 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 85 | |
P/E GROWTH RATING 1..100 | 15 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ANRO | XTLB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 74% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 88% | 7 days ago 76% |
| Declines ODDS (%) | 1 day ago 82% | 11 days ago 89% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANRO’s FA Score shows that 2 FA rating(s) are green while XTLB’s FA Score has 2 green FA rating(s).
- ANRO’s FA Score: 2 green, 3 red.
- XTLB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANRO’s TA Score shows that 4 TA indicator(s) are bullish while XTLB’s TA Score has 3 bullish TA indicator(s).
- ANRO’s TA Score: 4 bullish, 5 bearish.
- XTLB’s TA Score: 3 bullish, 3 bearish.
Price Growth
ANRO (@Biotechnology) experienced а +7.42% price change this week, while XTLB (@Biotechnology) price change was +0.51% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
ANRO is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ANRO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with NERV. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then NERV could also see price increases.
| Ticker / NAME | Correlation To ANRO | 1D Price Change % | ||
|---|---|---|---|---|
| ANRO | 100% | -4.80% | ||
| NERV - ANRO | 50% Loosely correlated | +0.42% | ||
| CELC - ANRO | 41% Loosely correlated | +6.51% | ||
| PRAX - ANRO | 38% Loosely correlated | +0.96% | ||
| IMTX - ANRO | 37% Loosely correlated | -1.95% | ||
| SPRB - ANRO | 37% Loosely correlated | +7.65% | ||
More | ||||